We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Ovarian Cancer Test Exhibits Exceptional Accuracy

By LabMedica International staff writers
Posted on 23 Aug 2010
A new technique correctly identified women with ovarian cancer in 100% of the patients tested using mass spectrometry analysis of one drop of blood. More...


The measurement step in the test used 200 μL of blood serum, which is vaporized by hot helium plasma. As the molecules from the serum become electrically charged, a mass spectrometer is used to measure their relative abundance.

The test looks at metabolites in the serum. Sera were obtained from 44 women with ovarian cancer, and 50 women with either benign conditions or were healthy. The sera were analyzed by high throughput ambient ionization technique for mass spectrometry. This gives direct real time analysis of the profile relative metabolites levels in the sera. The profiles were input to a customized functional support vector machine–based machine-learning algorithm for diagnostic classification. Performance was evaluated through a 64-30 split validation test and with a stringent series of leave-one-out cross-validations.

The scientists at Georgia Institute of Technology, (Atlanta, GA, USA), reported that the assay did extremely well in initial tests involving 94 subjects. In addition to being able to generate results using only a drop of blood serum, the test proved to be 100% accurate in distinguishing sera from women with ovarian cancer from normal controls. In addition, it registered neither a single false positive nor a false negative.

John McDonald, Ph.D. the Chief Research Scientist at Georgia Tech., said, "Because ovarian cancer is a disease of relatively low prevalence, it is essential that tests for it be extremely accurate. We believe we may have developed such a test." The results of the study were published online in July 2010 in the journal Cancer Epidemiology, Biomarkers, & Prevention Research. In addition to having a relatively low prevalence, ovarian cancer is also asymptomatic in the early stages. Therefore, if further testing confirms the ability to accurately detect ovarian cancer by analyzing metabolites in the serum of women, doctors will be able detect the disease early and save many lives.

Related Links:
Georgia Institute of Technology



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.